成人起病妇科癌症幸存者慢性病药物使用发生率与患病率:全国性队列研究
妇科癌症患者止痛药发生率高于无癌女性,诊断后至少10年性激素患病率高(宫颈癌PR=23,卵巢癌PR=29),子宫体癌患者抗糖尿病药患病率更高。
要点
- 妇科癌症幸存者止痛药使用发生率高于无癌女性,尤其诊断后前5年,患病率至少持续10年。
- 宫颈癌和卵巢癌幸存者诊断后至少10年性激素患病率分别为PR=23和PR=29,无癌女性为0.3%。
- 子宫体癌患者诊断前后抗糖尿病药患病率均更高,50岁前诊断者PR=10。
核心结论
- 妇科癌症幸存者,尤其是宫颈癌和卵巢癌幸存者,长期止痛药和性激素使用增加。
- 子宫体癌幸存者诊断前后抗糖尿病药使用更频繁。
研究设计与样本
- 前瞻性研究,基于挪威癌症登记处与挪威处方数据库等国家数据库链接。
主要发现
- 妇科癌症患者止痛药发生率高于无癌女性,尤其诊断后前5年,患病率至少持续至诊断后10年。
- 宫颈癌和卵巢癌患者诊断后至少10年性激素患病率分别为PR=23(95% CI 18-30)和PR=29(95% CI 15-38),无癌女性为0.3%。
- 子宫体癌患者诊断前及诊断后至少10年抗糖尿病药患病率更高,50岁前诊断者最显著(PR=10,95% CI 5.0-21)。
- 妇科癌症患者抗抑郁药患病率中度升高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate both incidence and prevalence of drugs used for chronic diseases in survivors of adult-onset gynaecological cancer. DESIGN: A prospective study. SETTING: Population-based registries. POPULATION: 1.76 million women, including 17 500 women with gynaecological cancers. METHODS: Data from the Cancer Registry of Norway was linked to the Norwegian Prescription Database and other national databases. MAIN OUTCOME MEASURES: Prevalence ratios (PRs) and hazard ratios (HRs), with 95% confidence intervals (CIs), of dispensed drugs in gynaecological cancer patients (up to 15 years after diagnosis) were estimated by log-binomial and Cox regression, respectively, with cancer-free women as reference. RESULTS: For gynaecological cancer patients, the incidence of drugs used for pain control was higher than in cancer-free women, especially the first 5 years after diagnosis, and the prevalence was high at least 10 years after. The prevalence of sex hormones was high in women with gynaecological cancer at least 10 years after diagnosis (cervical and ovarian cancer PR = 23, 95% CI 18-30 and PR = 29, 95% CI 15-38, respectively), but low in cancer-free women (0.3%). Patients with uterine corpus cancer had a higher prevalence of antidiabetics before and at least 10 years after diagnosis, most pronounced in women diagnosed before age 50 (PR = 10, 95% CI 5.0-21). The prevalence of antidepressants was moderately elevated in women with gynaecological cancers. CONCLUSIONS: Gynaecological cancer survivors, particularly cervical and ovarian cancer survivors, had an increased long-term use of drugs for pain control and sex hormones. Survivors of uterine corpus cancer used antidiabetics more often, both before and after diagnosis.
引用
- Bjørge T, Hjellvik V, Bjørge L, et al. Incidence and prevalence of drugs used for chronic diseases in survivors of adult-onset gynaecological cancer - A nationwide cohort study. BJOG. 2023. PMID: 36700296. doi:10.1111/1471-0528.17410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。